Probiotics and the Neurodevelopment in the Premature Infant <32 Weeks Gestational Age and <1500g
- Conditions
- Infant, Newborn, DiseasesInfant Development
- Interventions
- Dietary Supplement: Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748
- Registration Number
- NCT05945017
- Lead Sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Brief Summary
Unicentric, quasi-experimental, cohort study to evaluate the effect of combining two probiotics (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748) in the neurodevelopment of preterm neonates below 32 weeks' gestation and a birthweight under 1,500 g. This probiotic combination has shown to be safe and beneficial in premature neonates in the prevention of NEC. The investigators hypothesised that this mixture would contribute to better neurodevelopmental outcomes of preterm neonates when assessed at 24 months corrected age. Additionally, neurodevelopment improved would be more relevant at 6 years of age, together with a better pattern of neuronal plasticity biomarkers.
Secondarily, this mixture of probiotics could reduce NEC, LOS, intraventricular haemorrhage and neonatal mortality in accordance with previous studies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 233
- Premature infants under 32 weeks gestational age and less than 1500g birthweight.
- Born at BCNatal Hospital Clínic between years 2014-2019.
- All neonates presenting with suspected congenital anomalies, inborn errors of metabolism, or genetic defects were excluded.
- Infants with a suspected syndrome, or who have suffered events beyond the neonatal period, not related to prematurity, that could entail impairment in neurodevelopment (severe cranioencephalic trauma, oncological process, meningitis, or exposure to toxic substances)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748 Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748 Daily dose of 6x109 UFC Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748) from 7 days of life until reaching a postmenstrual age of 34 weeks or discharge
- Primary Outcome Measures
Name Time Method Degree of neurodevelopment at 6 years of age 6 years Behavior Rating Inventory of Executive Function, Second Edition (BRIEF2). Parent/teacher self reporting form.
Neuroplasticity biomarkers and intestinal permeability 6 years NeuN, Doublecortin, GFAP, GDNF, Ki67, Nrf2, BDNF, NGF, neurotrophin-1 (NT-1), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), DYRK1A, HIF1α, S100B i GSK3B. IL1B, IL6, IL8, IL10, IL12, TNF- α
Degree of neurodevelopment at 24 months corrected age 24 months Severe impairment will be attributed to subjects with any of the following: spastic quadriplegia, choreoathetosis, ataxia, Bayley score \<50, blindness or severe hypoacusis
- Secondary Outcome Measures
Name Time Method Incidence of necrotising enterocolitis 40 weeks cases fulfilling the stage II or above of the modified Bell's Criteria
Incidence of late onset sepsis 40 weeks positive blood culture beyond 72 hours of life
Incidence of Intraventricular haemorrhage 40 weeks Grade I-IV
Mortality 40 weeks Proportion of dead participants before discharge
Intensive care length of stay 40 weeks Days of intensive care
Trial Locations
- Locations (1)
Neonataology Service, BCNatal Hospital Clinic Seu Maternitat
🇪🇸Barcelona, Spain